Electrophysiology of oral encainide

Warren M. Jackman, Douglas P. Zipes, Gerald V. Naccarelli, Robert L. Rinkenberger, James J. Heger, Eric N. Prystowsky

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The electrophysiologic effects of oral encainide were assessed in 15 patients. Electrophysiologic studies were performed before and after 3 or more days of oral encainide therapy, 100 to 300 mg/day (mean 242 ± 66). Patients received no other cardioactive drugs during this time. Encainide significantly (p < 0.005) lengthened the following: A-H interval (74.5 ± 21.5 to 105.5 ± 39.1 ms, mean ± standard deviation), the shortest atrial pacing cycle length maintaining 1:1 atrioventricular (A-V) nodal conduction (339.0 ± 71.3 to 417.0 ± 88.6 ms), H-V interval (47.5 ± 7.8 to 67.1 ± 12.9 ms), QRS interval (103.5 ± 30.9 to 132.3 ± 35.7 ms), right atrial (233.8 ± 27.2 ms to 282.9 ± 38.6 ms) and right ventricular (235.7 ± 15.6 to 267.1 ± 36.9 ms) effective refractory periods and Q-T interval (364.4 ± 38.0 to 416.9 ± 55.3 ms). The spontaneous sinus cycle length did not change significantly. In four patients who had accessory A-V muscle connections (two manifest, two concealed) encainide abolished anterograde conduction over the accessory pathway in two patients, and increased the retrograde effective refractory period and/or lengthened retrograde conduction time or blocked retrograde conduction in the accessory pathway, or all three variables, in all four patients. There was no correlation between the plasma encainide concentration obtained at the time of study and the magnitude of change in any electrophysiologic variable. It is concluded that (1) encainide depresses conduction in the A-V node, His-Purkinje system and accessory pathway, and increases refractoriness of the atrium, ventricle and accessory pathway, and (2) differences between these results and those of earlier studies using encainide in a single intravenous dose (which found no significant effects on A-V nodal conduction or atrial and ventricular refractoriness) may be explained in part by the effects of an active metabolite of encainide.

Original languageEnglish (US)
Pages (from-to)1270-1278
Number of pages9
JournalThe American journal of cardiology
Volume49
Issue number5
DOIs
StatePublished - Apr 1 1982

Fingerprint

Encainide
Electrophysiology
Atrioventricular Node
Time and Motion Studies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Jackman, W. M., Zipes, D. P., Naccarelli, G. V., Rinkenberger, R. L., Heger, J. J., & Prystowsky, E. N. (1982). Electrophysiology of oral encainide. The American journal of cardiology, 49(5), 1270-1278. https://doi.org/10.1016/0002-9149(82)90055-8
Jackman, Warren M. ; Zipes, Douglas P. ; Naccarelli, Gerald V. ; Rinkenberger, Robert L. ; Heger, James J. ; Prystowsky, Eric N. / Electrophysiology of oral encainide. In: The American journal of cardiology. 1982 ; Vol. 49, No. 5. pp. 1270-1278.
@article{1ff56c9c7eaa4ce2a1c1f152efea0230,
title = "Electrophysiology of oral encainide",
abstract = "The electrophysiologic effects of oral encainide were assessed in 15 patients. Electrophysiologic studies were performed before and after 3 or more days of oral encainide therapy, 100 to 300 mg/day (mean 242 ± 66). Patients received no other cardioactive drugs during this time. Encainide significantly (p < 0.005) lengthened the following: A-H interval (74.5 ± 21.5 to 105.5 ± 39.1 ms, mean ± standard deviation), the shortest atrial pacing cycle length maintaining 1:1 atrioventricular (A-V) nodal conduction (339.0 ± 71.3 to 417.0 ± 88.6 ms), H-V interval (47.5 ± 7.8 to 67.1 ± 12.9 ms), QRS interval (103.5 ± 30.9 to 132.3 ± 35.7 ms), right atrial (233.8 ± 27.2 ms to 282.9 ± 38.6 ms) and right ventricular (235.7 ± 15.6 to 267.1 ± 36.9 ms) effective refractory periods and Q-T interval (364.4 ± 38.0 to 416.9 ± 55.3 ms). The spontaneous sinus cycle length did not change significantly. In four patients who had accessory A-V muscle connections (two manifest, two concealed) encainide abolished anterograde conduction over the accessory pathway in two patients, and increased the retrograde effective refractory period and/or lengthened retrograde conduction time or blocked retrograde conduction in the accessory pathway, or all three variables, in all four patients. There was no correlation between the plasma encainide concentration obtained at the time of study and the magnitude of change in any electrophysiologic variable. It is concluded that (1) encainide depresses conduction in the A-V node, His-Purkinje system and accessory pathway, and increases refractoriness of the atrium, ventricle and accessory pathway, and (2) differences between these results and those of earlier studies using encainide in a single intravenous dose (which found no significant effects on A-V nodal conduction or atrial and ventricular refractoriness) may be explained in part by the effects of an active metabolite of encainide.",
author = "Jackman, {Warren M.} and Zipes, {Douglas P.} and Naccarelli, {Gerald V.} and Rinkenberger, {Robert L.} and Heger, {James J.} and Prystowsky, {Eric N.}",
year = "1982",
month = "4",
day = "1",
doi = "10.1016/0002-9149(82)90055-8",
language = "English (US)",
volume = "49",
pages = "1270--1278",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

Jackman, WM, Zipes, DP, Naccarelli, GV, Rinkenberger, RL, Heger, JJ & Prystowsky, EN 1982, 'Electrophysiology of oral encainide', The American journal of cardiology, vol. 49, no. 5, pp. 1270-1278. https://doi.org/10.1016/0002-9149(82)90055-8

Electrophysiology of oral encainide. / Jackman, Warren M.; Zipes, Douglas P.; Naccarelli, Gerald V.; Rinkenberger, Robert L.; Heger, James J.; Prystowsky, Eric N.

In: The American journal of cardiology, Vol. 49, No. 5, 01.04.1982, p. 1270-1278.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Electrophysiology of oral encainide

AU - Jackman, Warren M.

AU - Zipes, Douglas P.

AU - Naccarelli, Gerald V.

AU - Rinkenberger, Robert L.

AU - Heger, James J.

AU - Prystowsky, Eric N.

PY - 1982/4/1

Y1 - 1982/4/1

N2 - The electrophysiologic effects of oral encainide were assessed in 15 patients. Electrophysiologic studies were performed before and after 3 or more days of oral encainide therapy, 100 to 300 mg/day (mean 242 ± 66). Patients received no other cardioactive drugs during this time. Encainide significantly (p < 0.005) lengthened the following: A-H interval (74.5 ± 21.5 to 105.5 ± 39.1 ms, mean ± standard deviation), the shortest atrial pacing cycle length maintaining 1:1 atrioventricular (A-V) nodal conduction (339.0 ± 71.3 to 417.0 ± 88.6 ms), H-V interval (47.5 ± 7.8 to 67.1 ± 12.9 ms), QRS interval (103.5 ± 30.9 to 132.3 ± 35.7 ms), right atrial (233.8 ± 27.2 ms to 282.9 ± 38.6 ms) and right ventricular (235.7 ± 15.6 to 267.1 ± 36.9 ms) effective refractory periods and Q-T interval (364.4 ± 38.0 to 416.9 ± 55.3 ms). The spontaneous sinus cycle length did not change significantly. In four patients who had accessory A-V muscle connections (two manifest, two concealed) encainide abolished anterograde conduction over the accessory pathway in two patients, and increased the retrograde effective refractory period and/or lengthened retrograde conduction time or blocked retrograde conduction in the accessory pathway, or all three variables, in all four patients. There was no correlation between the plasma encainide concentration obtained at the time of study and the magnitude of change in any electrophysiologic variable. It is concluded that (1) encainide depresses conduction in the A-V node, His-Purkinje system and accessory pathway, and increases refractoriness of the atrium, ventricle and accessory pathway, and (2) differences between these results and those of earlier studies using encainide in a single intravenous dose (which found no significant effects on A-V nodal conduction or atrial and ventricular refractoriness) may be explained in part by the effects of an active metabolite of encainide.

AB - The electrophysiologic effects of oral encainide were assessed in 15 patients. Electrophysiologic studies were performed before and after 3 or more days of oral encainide therapy, 100 to 300 mg/day (mean 242 ± 66). Patients received no other cardioactive drugs during this time. Encainide significantly (p < 0.005) lengthened the following: A-H interval (74.5 ± 21.5 to 105.5 ± 39.1 ms, mean ± standard deviation), the shortest atrial pacing cycle length maintaining 1:1 atrioventricular (A-V) nodal conduction (339.0 ± 71.3 to 417.0 ± 88.6 ms), H-V interval (47.5 ± 7.8 to 67.1 ± 12.9 ms), QRS interval (103.5 ± 30.9 to 132.3 ± 35.7 ms), right atrial (233.8 ± 27.2 ms to 282.9 ± 38.6 ms) and right ventricular (235.7 ± 15.6 to 267.1 ± 36.9 ms) effective refractory periods and Q-T interval (364.4 ± 38.0 to 416.9 ± 55.3 ms). The spontaneous sinus cycle length did not change significantly. In four patients who had accessory A-V muscle connections (two manifest, two concealed) encainide abolished anterograde conduction over the accessory pathway in two patients, and increased the retrograde effective refractory period and/or lengthened retrograde conduction time or blocked retrograde conduction in the accessory pathway, or all three variables, in all four patients. There was no correlation between the plasma encainide concentration obtained at the time of study and the magnitude of change in any electrophysiologic variable. It is concluded that (1) encainide depresses conduction in the A-V node, His-Purkinje system and accessory pathway, and increases refractoriness of the atrium, ventricle and accessory pathway, and (2) differences between these results and those of earlier studies using encainide in a single intravenous dose (which found no significant effects on A-V nodal conduction or atrial and ventricular refractoriness) may be explained in part by the effects of an active metabolite of encainide.

UR - http://www.scopus.com/inward/record.url?scp=0019963914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019963914&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(82)90055-8

DO - 10.1016/0002-9149(82)90055-8

M3 - Article

C2 - 6801954

AN - SCOPUS:0019963914

VL - 49

SP - 1270

EP - 1278

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -

Jackman WM, Zipes DP, Naccarelli GV, Rinkenberger RL, Heger JJ, Prystowsky EN. Electrophysiology of oral encainide. The American journal of cardiology. 1982 Apr 1;49(5):1270-1278. https://doi.org/10.1016/0002-9149(82)90055-8